Merck & Co Inc. (MRK) reported significant results from its Phase 3 KEYNOTE-522 trial, indicating that its anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in combination with chemotherapy before surgery and continued as monotherapy after surgery, reduced the mortality risk by 34% compared to neoadjuvant chemotherapy alone. This trial focused on patients with high-risk early-stage triple-negative breast cancer (TNBC).The five-year overall survival rate stood at 86.6% for those administered the KEYTRUDA regimen, compared to 81.7% for those on the chemotherapy-placebo regimen. Notably, median overall survival was not reached in either cohort. The safety profile of KEYTRUDA remained consistent with previous findings, with no new safety concerns reported.Earlier in the study, KEYNOTE-522 had already met its primary endpoints of pathologic complete response (pCR) and event-free survival (EFS).The material has been provided by InstaForex Company – www.instaforex.com
- Oracle To Invest More Than $6.5 Bln In Malaysia For AI And Cloud Services - October 2, 2024
- Romania’s Producer Price Index Sees Slight Uptick in August 2024 - October 2, 2024
- Kenya’s GDP Growth Slows to 3.60% in Q2 2024 Amid Economic Headwinds - October 2, 2024
